MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
Why INAB Stock dropped -3.91% Today — RQD Quant Desk Flash
$0.98 -3.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.97
IN8bio Inc. (INAB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $9.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on INAB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.98 (-3.91% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #725 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does INAB compare to INTS and PASG in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for INAB?
▼
Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.97 (-0.89%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-11.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INAB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY INAB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.23-11.4% Next Q
42
Q2 (-2Q)Grade E$1.09-11% Next Q
39
Q3 (-1Q)Grade E$0.97+1% Next Q
37
CurrentGrade E$0.98-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a INAB Turnaround Squeeze
While INAB currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.15) and Max Pain ($1.03) forces dealer call-delta covering toward $2.87.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $INAB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INAB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why INAB Stock dropped -3.91% Today — RQD Quant Desk Flash
IN8bio Inc. (INAB) dropped -3.91% to $0.98, trading at 6% of its 52-week range ($0.87 – $2.73). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 6% of its 52-week range ($0.87 – $2.73) with RSI-14 at 40.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.98 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live INAB Headlines & Catalysts
MARKET WIREReuters • 2h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 3h ago
Gold rises on softer oil; markets parse Fed signals - ReutersGold rises on softer oil; markets parse Fed signals Reuters
MARKET WIREReuters • 4h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
CATALYSTReuters • 6h ago
Indian shares rise on Iran war talks, Reliance earnings beat - ReutersIndian shares rise on Iran war talks, Reliance earnings beat Reuters
CATALYSTReuters • 8h ago
Bank of England poised to raise rates but may push back on bets for more - ReutersBank of England poised to raise rates but may push back on bets for more Reuters
MARKET WIREReuters • 9h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Oil prices ease 3% on optimism for Qatari-led talks on ending Iran war - ReutersOil prices ease 3% on optimism for Qatari-led talks on ending Iran war Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INAB)
- ✓Walkthrough of INAB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
INAB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -39.13%📐 HORIZONTAL RANGE
2026-11-02O $1.02H $1.02L $0.98C $0.98VOL 1.4K
RES: $1.58SUP: $0.86SMA50: $1.15SMA200: $1.45
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
INAB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on INAB today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for INAB. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INAB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INAB)
Health Care Rank #725 of 1016
⚔️ INTS vs INAB Full Matrix →
1. Head-to-Head Health Care Peer Comparison (INAB vs. INTS, PASG, ATYR, BCDA)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, IN8bio Inc. (INAB) ranks #725 by composite RQD confidence (34/100, grade E) and #898 by equity capitalization ($9.7M). Within this direct 5-issuer industry benchmark cohort, INAB leads on earnings valuation at N/A trailing P/E, while INAB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ATYR currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with INAB at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INAB
ACTIVE
IN8bio Inc. | E | 34/100 | — | — | -35.0% | -3.91% | $9.7M | Benchmark Subject |
| INTS Intensity Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | -1.18% | $10.9M | /ints-vs-inab → |
| PASG Passage Bio Inc. | E | 34/100 | — | — | -35.0% | +5.71% | $11.3M | /pasg-vs-inab → |
| ATYR aTyr Pharma Inc. | D | 45/100 | — | — | -35.0% | +4.56% | $13.5M | /atyr-vs-inab → |
| BCDA BioCardia Inc. | D- | 38/100 | — | — | -35.0% | -2.26% | $14.0M | /bcda-vs-inab → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001740279In its most recent audited fiscal period (FY2025, filed 2025-12-31), IN8bio Inc. (INAB) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$19.4M, operating cash flow of -$12.7M, and free cash flow of -$12.7M (+47.4% YoY). On the balance sheet, INAB closed FY2025 with $32.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$19.4M | -$12.7M | -$12.7M | $32.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$30.4M | -$24.1M | -$24.1M | $20.9M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$30.0M | -$23.3M | -$23.3M | — | — |
3. INAB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs INAB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, IN8bio Inc. (NASDAQ: INAB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.98 (-3.91% 1D, market cap $9.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, INAB ranks #725 in composite RQD confidence.
How does INAB compare to INTS and PASG in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INAB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INTS (Intensity Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $10.9M) and PASG (Passage Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $11.3M). Among the 5-stock peer group, INAB leads on earnings multiple (N/A) while INAB leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for INAB?
Per INAB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001740279), IN8bio Inc. generated $0 in revenue, -$19.4M in net income, and -$12.7M in free cash flow against $32.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is INAB trading relative to its 50-day, 200-day, and 52-week technical levels?
INAB last traded at $0.98 (-3.91% on volume of 1,419 shares), positioning the stock -14.78% below its 50-day simple moving average ($1.15) and -32.41% below its 200-day simple moving average ($1.45). Across its 52-week range of $0.87 to $2.73, INAB sits at the 5.9% percentile with a 14-day RSI of 40.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.10).
INAB Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is INAB stock moving today?
Why INAB Stock dropped -3.91% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.